GH Research Reports GH001 Significantly Reduces Depression and Anxiety in Treatment-Resistant Patients

GH Research plc has announced results from a Phase 2b multicenter clinical trial (NCT05800860) evaluating the efficacy and safety of GH001, a synthetic form of mebufotenin (5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) ) administered by pulmonary inhalation, in patients with treatment-resistant depression (TRD). The trial included a randomized, double-blind, placebo-controlled part and a six-month open-label extension. Data analysis, completed on August 12, 2025, showed that GH001 led to a significantly greater reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores compared to placebo at Day 8, as well as improvements in secondary endpoints including Clinical Global Impression-Severity (CGI-S), Hamilton Rating Scale for Anxiety (HAM-A), and quality of life (Q-LES-Q-SF). At six months, patients who completed the open-label extension maintained significant improvements in illness severity, anxiety symptoms, and quality of life. The results were presented by the study investigators, including Michael E. Thase. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-043042), on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here